PMID: 11604269Oct 18, 2001Paper

Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin

International Journal of Pharmaceutics
Y NagaseK Uekama

Abstract

The interaction of DY-9760e, a novel cytoprotective agent, with sulfobutyl ether beta-cyclodextrin (SBE-beta-CyD) in phosphate buffered saline (PBS) at various pH and ionic-strengths was studied by spectroscopic methods and the solubility method, and the results were compared with that of 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CyD). The circular dichroism (CD) spectroscopic studies suggested that both beta-CyDs form the inclusion complexes with DY-9760e in a molar ratio of 1:1, and the interaction of DY-9760e with SBE-beta-CyD is much stronger than that with HP-beta-CyD at any pH studied, in terms of a synergetic effect of hydrophobic and electrostatic interactions. The different intermolecular interaction between the SBE-and HP-beta-CyD complexes was clearly reflected in the stability constant (K'), e.g. the different dependence of K' value on pH and ionic strength of solutions. 1H- and 13C-NMR studies suggested that HP-beta-CyD interacts preferably with the benzene ring of DY-9760e, whereas SBE-beta-CyD interacts not only with the benzene ring via hydrophobic interaction but also with the piperazine ring of the drug via electrostatic interaction. The solubilizing ability of SBE-beta-CyD against DY-9760e was much greater t...Continue Reading

References

Oct 1, 1996·Journal of Pharmaceutical Sciences·T Loftsson, M E Brewster
Jan 1, 1997·Critical Reviews in Therapeutic Drug Carrier Systems·D O Thompson
Feb 12, 1998·European Journal of Pharmacology·M SugimuraY Shirasaki
Jan 1, 1995·Critical Reviews in Therapeutic Drug Carrier Systems·E Albers, B W Müller
May 20, 1999·Pharmacotherapy·D A Stevens
Jun 6, 2000·Advanced Drug Delivery Reviews·L Szente, J Szejtli
Feb 19, 2002·Chemical Reviews·Kaneto UekamaTetsumi Irie

❮ Previous
Next ❯

Citations

Dec 16, 2005·AAPS PharmSciTech·Rajeswari ChallaR K Khar
Aug 12, 2004·Chemical & Pharmaceutical Bulletin·Kaneto Uekama
Dec 4, 2004·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kaneto Uekama
Jan 5, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kaneto Uekama
Mar 6, 2004·Drug Development and Industrial Pharmacy·Linda A FeltonDonald A Godwin
Dec 18, 2003·Drug Development and Industrial Pharmacy·Han-Gon ChoiChul-Soon Yong
Aug 9, 2007·Expert Opinion on Drug Delivery·Alfred Fahr, Xiangli Liu
Aug 4, 2011·Expert Opinion on Drug Delivery·Abhishek SinghGuy Van den Mooter
Jun 23, 2015·Expert Opinion on Drug Delivery·Hidetoshi ArimaKeiichi Motoyama
Nov 29, 2002·Drug Development and Industrial Pharmacy·Linda A FeltonDonald A Godwin
Oct 16, 2002·Journal of Pharmaceutical Sciences·Y NagaseK Uekama
May 8, 2015·Chemical & Pharmaceutical Bulletin·Yasuo InoueKaneto Uekama
Sep 12, 2006·Cardiovascular Drug Reviews·Kohji FukunagaYasufumi Shirasaki
May 27, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Avital BeigArik Dahan
Jan 13, 2015·International Journal of Pharmaceutics·Shashi Ravi Suman RudrangiStephen Richard Wicks
Sep 3, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Donald A GodwinLinda A Felton

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.